Skip to main content
SpringerLink
Log in

Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn’s Disease Treated Early with Thiopurines

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Impact of first-line induction therapy on medium-term outcomes in the setting of early thiopurine (TP) use in children with Crohn’s disease has not been evaluated, in particular whether choice of exclusive enteral nutrition (EEN) over corticosteroids (CS) for induction impacts clinical outcomes at 12 and 24 months.

Aims and Methods

In this retrospective study, 89 children from our database with new diagnosis CD and follow-up of at least 2 years following induction with exclusive course of CS or EEN and early, dose-optimized TP (within 6 months from diagnosis) were evaluated. We compared steroid dependency (relapse <3 months of tapering first course CS or inability to wean <10 mg prednisolone), need for IFX, linear growth, and surgical resections over the first 2 years.

Results

Choice of EEN over CS induction was associated with reduced linear growth failure (7 vs. 26 %, p = 0.02), CS dependency (7 vs. 43 %, p = 0.002), and improved primary sustained response to IFX (86 vs. 68 %, p = 0.02). Combined CS/IFX-free remission and surgical resection rates were similar.

Conclusion

In the setting of early TP commencement, EEN induction is superior to CS induction for reducing growth failure, CS dependency, and loss of response to IFX over the first 2 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–1113.

    Article  PubMed  Google Scholar 

  2. Peneau A, Salleron J, Fumery M, et al. P137, Long term outcome of pediatric onset Crohn’s disease: A population based study, ECCO abstracts 2012.

  3. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.

    Article  PubMed  Google Scholar 

  4. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–961.

    Article  PubMed  Google Scholar 

  5. Whelan G, Farmer RG, Fazio VW, et al. Recurrence after surgery in Crohn’s disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology. 1985;88:1826–1833.

    CAS  PubMed  Google Scholar 

  6. Castile RG, Telander RL, Cooney D, et al. Crohn’s disease in children: assessment of the progression of disease, growth, and prognosis. J Pediatr Surg. 1980;15:462–469.

    Article  CAS  PubMed  Google Scholar 

  7. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207.

    Article  PubMed  Google Scholar 

  8. Markowitz J, Grancher K, Kohn N, Lesser M, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895.

    Article  CAS  PubMed  Google Scholar 

  9. Jaspers G, Verkade H, Escher J, et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn’s disease. Inflamm Bowel Dis. 2006;12:831–836.

    Article  PubMed  Google Scholar 

  10. Waters T, Kim M, Denson L, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146:383–391.

    Article  Google Scholar 

  11. Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–2143.

    Article  PubMed  Google Scholar 

  12. Boyle B, Kappelman M, Colletti R, et al. Routine use of thiopurines in maintaining remission in paediatric Crohn’s disease. World J Gastroenterol. 2014;20:9185–9190.

    PubMed Central  PubMed  Google Scholar 

  13. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145:758–765.

    Article  CAS  PubMed  Google Scholar 

  14. Panes J, Lopez-Sanroma A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145:766–774.

    Article  CAS  PubMed  Google Scholar 

  15. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.

    Article  PubMed  Google Scholar 

  16. Lee J, Escher J, Shuman M, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis. 2010;16:1669–1677.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Cole TJ, Flegal KM, Nicholls D, et al. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ. 2007;335:194–202.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Hyams J, Ferry G, Mandel F, et al. Development and validation of paediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439–447.

    CAS  PubMed  Google Scholar 

  19. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416–421.

    Article  PubMed  Google Scholar 

  20. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.

    Article  PubMed  Google Scholar 

  21. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.

    Article  CAS  PubMed  Google Scholar 

  22. Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease. J Gastroenterol. 2014;49:638–645.

    Article  CAS  PubMed  Google Scholar 

  23. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.

    Article  PubMed  Google Scholar 

  24. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–713.

    Article  CAS  PubMed  Google Scholar 

  25. Grover Z, Biron R, Carman N, et al. Predictors of response to infliximab in children with luminal Crohn’s disease. J Crohns Colitis. 2014;8:739–746.

    Article  PubMed  Google Scholar 

  26. Sazuka S, Katsuno T, Nakagawa T, et al. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn’s disease. Eur J Clin Nutr. 2012;66:1219–1223.

    Article  CAS  PubMed  Google Scholar 

  27. Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and Infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013;58:1329–1334. doi:10.1007/s10620-012-2374-2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Lambert B, Lemberg A, Leach ST, et al. Longer-term outcomes of nutritional management of Crohn’s disease in children. Dig Dis Sci. 2012;57:2171–2177. doi:10.1007/s10620-012-2232-2.

    Article  CAS  PubMed  Google Scholar 

  29. Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis.. 2006;38:381–387.

    Article  CAS  PubMed  Google Scholar 

  30. Cameron F, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;37:622–629.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Dr. Zubin Grover received ANZ trustees PHD and Queensland Children Medical Research Scholarship. He is a Paediatric Gastroenterology Advisory Board member for Abbvie. A/Prof Peter Lewindon is on Advisory Board panel of Janseen and Abbvie.

Author information

Authors and Affiliations

  1. Princess Margaret Hospital for Children, Perth, Australia

    Zubin Grover

  2. University of Queensland School of Medicine, Brisbane, QLD, Australia

    Peter Lewindon

Authors
  1. Zubin Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Lewindon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zubin Grover.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 11 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grover, Z., Lewindon, P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn’s Disease Treated Early with Thiopurines. Dig Dis Sci 60, 3069–3074 (2015). https://doi.org/10.1007/s10620-015-3722-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3722-9

Keywords

Search

Navigation